指南与共识产科母胎医学

母胎医学会咨询系列第69号:妊娠期乙型肝炎:更新指南

Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines.
指南 / 共识 · Am J Obstet Gynecol · 2023-12-22

该指南由母胎医学会制定,针对妊娠期乙型肝炎的筛查、围产期风险、治疗指征及疫苗接种提出10条推荐。推荐包括初次产检行三联检测(GRADE 1C)、普遍表面抗原筛查(GRADE 1B)、病毒载量>200,000 IU/mL者在妊娠28-32周启动替诺福韦治疗(GRADE 1B)、新生儿出生12小时内接种疫苗和免疫球蛋白(GRADE 1B)等。

要点

  • 初次产检推荐三联检测(表面抗原、表面抗体、核心总抗体)(GRADE 1C)。
  • 病毒载量>200,000 IU/mL者妊娠28-32周启动替诺福韦治疗(GRADE 1B)。
  • 新生儿出生12小时内接种乙肝疫苗和免疫球蛋白(GRADE 1B)。

核心结论

  • 指南推荐对孕妇进行乙肝感染和免疫状态筛查,并对符合指征者进行抗病毒治疗和新生儿免疫预防。

研究设计与样本

  • 母胎医学会制定,以咨询系列形式发布妊娠期乙型肝炎更新指南。

主要发现

  • 美国妊娠期慢性乙肝感染患病率估计为0.7%至0.9%,每年超过25,000名婴儿因围产期传播面临慢性感染风险。

关键数值与推荐

  • 推荐初次产检时行三联检测(乙肝表面抗原、表面抗体、核心总抗体)(GRADE 1C)。
  • 推荐对既往三联检测阴性者初次产检时单独行乙肝表面抗原普遍筛查(GRADE 1B)。
  • 推荐表面抗原筛查状态未知者在妊娠期任何就诊时检测;有临床肝炎或急性乙肝感染风险因素者在预计分娩入院时检测(GRADE 1B)。
  • 不推荐改变慢性乙肝感染者的常规产时护理;新生儿免疫预防是标准做法(GRADE 1B)。
  • 不推荐仅以降低围产期乙肝病毒传播为目的行剖宫产(GRADE 1B)。

临床怎么用

  • 乙肝感染者只要婴儿出生时接受免疫预防即可母乳喂养(GRADE 1C)。
  • 建议乙肝感染者如需侵入性检测,可在共享决策下充分讨论风险获益及检测对临床护理的影响后进行(GRADE 2C)。
  • 病毒载量>200,000 IU/mL(>5.3 log10 IU/mL)者,推荐妊娠晚期(28-32周启动)使用替诺福韦(替诺福韦艾拉酚胺25 mg每日或替诺福韦二吡呋酯300 mg每日)抗逆转录病毒治疗,作为免疫预防的辅助策略以减少围产期传播(GRADE 1B)。
  • 推荐对乙肝表面抗原阳性或状态未知/未记录孕妇的所有新生儿,在出生12小时内接种乙肝疫苗和乙肝免疫球蛋白,无论孕妇妊娠期是否接受抗病毒治疗(GRADE 1B)。
  • 推荐对无血清学免疫证据或无疫苗接种记录的所有孕妇接种乙肝疫苗(GRADE 1C)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More than 290 million people worldwide, and almost 2 million people in the United States, are infected with hepatitis B virus, which can lead to chronic hepatitis B, a vaccine-preventable communicable disease. The prevalence of chronic hepatitis B infection in pregnancy is estimated to be 0.7% to 0.9% in the United States, with >25,000 infants born annually at risk for chronic infection due to perinatal transmission. Given the burden of disease associated with chronic hepatitis B infection, recent national guidance has expanded both the indications for screening for hepatitis B infection and immunity and the indications for vaccination. The purpose of this document is to aid clinicians caring for pregnant patients in screening for hepatitis B infection and immunity status, discuss the perinatal risks of hepatitis B infection in pregnancy, determine whether treatment is indicated for maternal or perinatal indications, and recommend hepatitis B vaccination among susceptible patients. The following are the Society for Maternal-Fetal Medicine recommendations: (1) we recommend triple-panel testing (hepatitis B surface antigen screening, antibody to hepatitis B surface antigen, and total antibody to hepatitis B core antigen) at the initial prenatal visit if not previously documented or known to have been performed (GRADE 1C); (2) we recommend universal hepatitis B surface antigen screening alone at the initial prenatal care visit for all pregnancies where there has been a previously documented negative triple-panel test (GRADE 1B); (3) we recommend that individuals with unknown hepatitis B surface antigen screening status be tested on any presentation for care in pregnancy; we also recommend that those with clinical hepatitis or those with risk factors for acute hepatitis B infection be tested at the time of admission to a birthing facility when delivery is anticipated (GRADE 1B); (4) we do not recommend altering routine intrapartum care in individuals chronically infected with hepatitis B; administration of neonatal immunoprophylaxis is standard of care in these situations (GRADE 1B); (5) we do not recommend cesarean delivery for the sole indication of reducing perinatal hepatitis B virus transmission (GRADE 1B); (6) we recommend that individuals with HBV infection can breastfeed as long as the infant has received immunoprophylaxis at birth (GRADE 1C); (7) we suggest individuals with hepatitis B infection who desire invasive testing may have the procedure performed after an informed discussion on risks and benefits in the context of shared decision-making and in the context of how testing will affect clinical care (GRADE 2C); (8) in individuals with hepatitis viral loads >200,000 IU/mL (>5.3 log 10 IU/mL), we recommend antiretroviral therapy with tenofovir (tenofovir alafenamide at 25 mg daily or tenofovir disoproxil fumarate at 300 mg daily) in the third trimester (initiated at 28-32 weeks of gestation) as an adjunctive strategy to immunoprophylaxis to reduce perinatal transmission (GRADE 1B); (9) we recommend administering hepatitis B vaccine and hepatitis B immunoglobin within 12 hours of birth to all newborns of hepatitis B surface antigen-positive pregnant patients or those with unknown or undocumented hepatitis B surface antigen status, regardless of whether antiviral therapy has been given during the pregnancy to the pregnant patient (GRADE 1B); and (10) we recommend hepatitis B vaccination in pregnancy for all individuals without serologic evidence of immunity or documented history of vaccination (GRADE 1C).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Badell ML, Prabhu M, Dionne J, et al. Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines. Am J Obstet Gynecol. 2023. PMID: 38141870. doi:10.1016/j.ajog.2023.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。